AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.
Highlights - Glybera(R) Marketing Authorisation Application submitted to European Medicines Agency (EMA, formerly known as EMEA); - EMA commenced formal review of Glybera(R) dossier on January 20, 2010; - EMA grants orphan drug designation for AMT's Acute Intermittent Porphyria ("AIP") program; - EMA grants orphan drug designation for AMT's Duchenne Muscular Dystrophy ("DMD") program; - SenterNovem awards EUR 4 million investment credit for the development of AMT's DMD program; - Raised EUR 5 million convertible loan notes, which convert into ordinary shares at EUR 3.91 per share; - New management team.
Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we
announced a rebalancing of our strategy, focused on our lead product
Glybera(R), a proprietary product for lipoprotein lipase deficiency (LPLD),
together with the ongoing development of four earlier stage progams
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2010 PR Newswire.
All rights reserved